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Thymus-derived  (T) 1 cells are generally considered to play a  central role in  cell- 
mediated cytotoxicity against allografted tumors. Thus,  lymphocytes bearing recep- 
tors  for  antigen  and  responding  to  allografts are  thymus  derived  (1-4);  they  are 
required for the expression of cytotoxicity  during the immune response (5, 6) ; and edu- 
cated thymus-derived cells can act as killer cells even after purification on antibody- 
coated columns (2). 
Other circulating lymphocytes have also been demonstrated to act as killer cells in 
allograft reactions (see reference 7 for review). For example, antibody bound to target 
cells can  induce  cytotoxicity by activating bone  marrow-derived  (B)  lymphocytes 
(8,  9). 2 This antibody-induced cytotoxicity requires the binding of the Fc fragment 
of the bound immunoglobulin to effector lymphoeytes in order for killing to occur (10). 
While antibody-induced cytotoxicity can be readily demonstrated in vitro with sensi- 
tized target cells and nonimmune effector cells, few data are available to show that 
this event actually occurs in vivo after specific host sensitization (11-13). 
There is other evidence suggesting that more than one cell participates in the allo- 
graft response. Thus,  the cell(s) required for expressing cytotoxicity in spleens from 
immune mice vary with time after immunization in their sensitivity to X  irradiation 
(14).  Similar differences are noted with respect to cellular morphology, requirements 
for DNA synthesis, and killing efficiencies (14,  15).  However, these effects may also 
reflect the  characteristics of  one  cell at  different stages of maturation  rather  than 
different cell types. 
We decided to study the host response to an allografted lymphoma from the 
earliest possible time after host priming through  the peak and later stages  of 
the immune response in order to test whether T  cells were always required for 
the mediation of cytotoxicity. 
* Supported by a National Institutes of Health Fellowship (no. 5 F03 DE51836-02) from the 
National Institute of Dental Research. 
1 Abbreviations used in this paper: B cells, bone marrow-derived  cells; BSS, balanced salt 
solution;  EIS, early immune  spleens; GPC, guinea pig complement;  [125I]UdR, 125I-labeled 
iododeoxyuridine; LIS, late immune spleens; PFC, plaque-forming cells; SRBC, sheep erythro- 
cytes; T cells, thymus-derived cells. 
2 Britton, S., H. Perlmann, and P. Perlmann. Manuscript in preparation. 
TItE  JOURNAL OF  EXPERIMENTAL MEDICINE • VOLUME 137,  1973  369 370  EFFECTOR  CELLS  AGAINST  AN  ALLOGENEIC  LYMPE[OMA 
Materials and Methods 
Animals.-  A/Sn, CBA, and (A X  CBA)F1 mice between 2 and 4 mo of age were used. All 
were age matched and of the same sex for individual experiments. 
Tumors.--The YAC (H-2  a) Moloney virus-induced ascites leukemia was obtained from the 
Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden, and was used during 
its 220th-246th generation in vivo. 
Isotopes.-  [12~I]Iododeoxyuridine  ([12~I]UdR)  and  [51Cr]sodium chromate were  both ob- 
tained from Amersham/Searle Corp., Arlington Heights, Ill. 
Immunizations.-  Mice were imnmnized by intraperitoneal inoculation of either spleen cells 
or  107 live tumor cells. At varying time intervals thereafter, the animals were sacrificed and 
their spleens or mesenteric lymph nodes excised using sterile technique. A cell suspension was 
made in medium as described by Mishell and Dutton (16) and the number of viable cells was 
determined by trypan blue staining. 
Pretreatment of Cdls.--Spleen cells were pretreated with antitheta or normal (AKR) serum 
and complement. Antitheta serum was prepared as described by Greaves and MiSller (19) and 
different batches of such sera were  obtained  by bleeding mice at  different times. 50  X  10 ~ 
spleen cells were incubated with 0.5 ml of antitheta or AKR serum at a  1 : 1 or 1:3 dilution for 
15 min at 37°C, The cells were then washed, the pellet  resuspended in  1.0 ml of guinea pig 
complement (GPC)  that was preabsorbed with agarose (18) and mouse spleen and liver cells, 
and used at a  1:1 or 1:3 dilution. After rocking the suspension for 45 rain at 37°C, the cells 
were washed twice and the number of viable cells determined before use. In general, such treat- 
ments rendered between 20 and 38% spleen cells, 47 and 62%  lymph node cells, and 94 and 
97% thymus cells nonviable when CBA mice were used. 
In order  to remove phagocytic cells, some suspensions were pretreated  with carbonyl iron 
powder  according to the method of Lundgren et al.  (19).  After 30 rain incubation with the 
iron powder  at 37°C with rocking, the iron was extracted in several steps with the aid of a 
magnet and the cells were then washed twice before further experimental treatments. 
Labeling of Target Cells.--Peritoneal  YAC cells were removed under sterile conditions from 
(A)<  CBA)F1 tumor-bearing mice between 6 and 8 days after intraperitoneal inoculation of 
107 cells. The cells were washed once and placed in a  Falcon flask (no. 3024 Falcon Plastics, 
Oxnard, Calif.) at a concentration of 1.0~1.5 X  10 ~ cells/ml. The medium containing the cells 
was a  modified minimal essential medium with supplements (20) and also included 20% fetal 
bovine serum. To this suspension, [125I]UdR was added at a concentration of 0.07 #Ci/ml and 
the flask was rocked for 4 h at 37°C. The cells were then washed lwlce at low-speed centrifuga- 
tion  and  resuspended to  the appropriate  concentration in  balanced  salt  solution  (BSS).  In 
some experiments, cells were doubly labeled with  [~lCr]sodium chromate and  [t25I]UdR.  In 
order  to  do  this, the [L95I]UdR-labeled  cells were  suspended in 2  ml of medium with  '51Cr 
using 100 #Ci Cr/50  )<  106 cells. After 45 rain incubation at 37°C, the cells were washed six 
times before use. 
Cytotoxic Assays.-  The method used here follows the original description of the method for 
keeping mouse spleen cells alive in vitro  (16)  and is similar to that described by Canty and 
Wunderlich (21). Spleen cells were suspended in medium with 10% heat-inactivated fetal calf 
serum and 1 ml of the suspension was placed in 35-mm plastic Petri dishes. 0.1 ml of the tumor 
cell suspension (usually 105 cells) was then added to these dishes and they were placed in a 
sealed box with a gas mixture of nitrogen (83%), oxygen (7%), and carbon dioxide (10%) and 
rocked at 37°C. Unless otherwise indicated, the reactions were run for 16 h. The cell suspensions 
were  then removed from the individual Petri  dishes  (three dishes/group)  with the aid of a 
rubber policeman. This suspension was centrifuged and the entire supernatant removed care- 
fully with a disposable pipette and saved (first supernatant). The pellet was resuspended on a 
Vortex mixer and 0.3 ml of a 0.25% trypsin solution added. After 30 min incubation at 37°C, 
0.7 ml of cold BSS was added and the tube centrifuged. One-half of the supernatant was re- JAMES  FORMAN  AND  SVEN  BRITTON  371 
moved (second supernatant)  and these two supernatants as well as the tube containing the cell 
pellet were placed in a well-type gamma counter and the percent release of 12'5I was calculated 
using the formula (bk  =  background) : 
%  125I release  =  cpm 1st supernatant  -- bk +  2 (cpm 2nd supernatant  -- bk)  ;<  100 . 
cpm 1st +  2nd supernatant  +  pellet -  3 (bk) 
In some experiments the release of isotope was expressed  as a cytotoxic index: 
Cytotoxic index  = 
e/o release I25I with immune cells -  %  release  12~I with nonimmune cells 
X  100. 
%  release 125I with immune cells 
Local Hemolysis in Gel Assay.--The  technique originally described by Jerne and  Nordin 
and modified by Mishell and Dutton  (16) was used.  In each experimental group, cells from 
three dishes were pooled, spun once, and resuspended in cold BSS to a concentration suitable 
for the plaquing assay. The cells were mixe with the appropriate erythrocytes in agarose and 
the mixture poured onto glass  slides.  Duplicate slides were made for each group. For detec- 
tion of plaque-forming cells (PFC), the slides were incubated at 37°C for 3 h in the presence of 
GPC diluted 1:20 in BSS. 
Antigens.--Sheep erythrocytes  (SRBC)  were  prepared  and  used for the in vitro experi- 
ments as previously described (22). 107 SRBC in 30/zl was the immunizing dose and this was 
mixed with spleen cell suspensions  containing 10 X  106 cells in 1 ml in individual Petri dishes, 
The cultures were fed each day with a nutritional cocktail (23). In these experiments the spleen 
cells had been pretreated with antitheta or normal mouse serum and complement. 
Antibody Titrations.--Cytotoxic antibodies  were  determined  by  mixing  equal  volumes 
(0.05 ml) of antiserum in serial dilutions with YAC target cells (5)<  105) and incubating this 
mixture at 37°C for 30 rain.  The cells were then washed once and 0.1 ml of 1:3-diluted GPC 
absorbed with agarose (18) was added and the mixture was incubated at 37°C for another  45 
min. After this treatment,  cell death was determined either by trypan blue dye exclusion or 
51Cr isotope release. 
RESULTS 
Characteristics  of the Assay System.--In  these  experiments,  target  cells were 
labeled with  [~25I]UdR and  the percent  release of 125I from the  tumor  cells was 
used  to estimate cell death.  This method has been shown  to be a  reliable indi- 
cator of cell survival  (24)  and was used because the in vitro labeling procedure 
required a  minimum of handling of the target cells. When  [125I]UdR was added 
to  a  rocking  suspension  of YAC  cells,  65 %  of  the  label  was precipitable  with 
10%  trichloroacetic  acid  after  24  h  (Fig.  1).  However,  sufficient label  was  in- 
corporated  into  the cells (2000  cpm/10 ~ cells)  after 3-4 h  to  allow their use  as 
target cells in the assay. 
Release of radiolabel  from cells incubated  alone or with normal  spleen  cells 
was  between  15  and  25 %  after  16  h.  Target  cells incubated  with  specifically 
immune  cells released  isotope  in proportion  to  the effector to  target  cell ratio 
(Figs.  2  and  8).  Further,  when  YAC  cells  were  doubly  labeled  with  125I and 
5~Cr,  the  release  of both  isotopes  from  target  cells in  the presence  of immune 
cells was similar (Fig. 2). 372  EFFECTOR  CELLS  AGAINST  AN  ALLOGENE[C  LYMPHOMA 
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A  few precautions  were found to be important  when using this label  in the 
assay. Firstly, it was necessary to trypsinize the cells after the incubation period 
of the  test  to assist  in the  release  of some of the  label  from dead cells,  which 
probably had not disintegrated  sufficiently to liberate  their  nuclear  contents. 
Secondly,  the  cells  could not be labeled  with  a  high  concentration  of t~sI be- 
cause of the radiotoxic properties of this isotope (25). 
Characteristics  and  Specificity  of  the  Immune  Response  to  the  Allogeneic 
Lymphoma YAC.--CBA mice were divided into groups of three and inoculated 
intraperitoneally with 107 YAC cells on different days. Subsequently, the groups 
were  all  sacrificed  on  the  same  day,  the  spleens  pooled  within  each  group, 
and their cytotoxic activity evaluated from three replicate cultures per group. 
In Fig. 3  it  can be seen that lymphocytes from the immunized H-2  allogeneic 
mice developed  a  cytotoxic effect which peaked  between  7 and  14 days after 
priming. After this time there was a gradual decline in the degree of cytotoxicity 
reaching a minimum at day 32. Immunity was also detected with cells derived 
from the mesenteric lymph nodes (Table I). 
The specificity of this response was tested with  respect to H-2-  and  tumor- 
specific  immunity.  Specific  H-2  immunity  was  demonstrated  since  CBA 
FIG. 1.  Incorporation  of []2aI]UdR into YAC cells. Points  represent the percent of total 
12'51 activity not precipitable in 10% trichloracetic acid after addition of [12~I]UdR to a cul- 
tured suspension of YAC cells. JAMES  FORI~AN  AND  SVEN  BRITTON  373 
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FIG. 2.  Percent 125I and SlCr release from singly and doubly labeled YAC cells. Percent re- 
lease of 12sI -1- SEM  from YAC cells in the presence of nonimmune  (n) or immune  CBA spleen 
cells.  -----,  isotope  release from  YAC  ceils labeled with  [125I]UdR; --,  isotope  release from 
YAC cells labeled  with  [12sI]UdR  and  5tCr. 51Cr and  125I release  was  calculated  using  the 
formula  found  in the Materials  and Methods  section. 
(H-2  k) mice sensitized with A/Sn  (II-2  °) spleen ceils killed VAC  (H-2 a) target 
cells while A/Sn mice sensitized with CBA spleen cells did not (Table II). To 
test for tumor-specific immunity, CBA mice were sensitized with YAC or YBB 
cells,  the latter being a Moloney virus-induced lymphoma that originated in a 
CBA mouse. Here the response was also specific since after 3  days the spleens 
from mice sensitized with YAC showed a strong cytotoxic effect against YAC 
target  cells  while  those  primed  with  YBB  showed  only  a  very  weak  effect 
(Table  II). 
Effect of A ntitheta Serum on Cell-Mediated Cytotoxicity.--Mice were inoculated 
with  10  7 YAC  cells  intraperitoneally.  At  varying  time  intervals  thereafter, 
groups  containing  three mice each  were sacrificed;  their  spleens  were pooled 
and  then  treated  with  samples from  a  pool  of  antitheta  or  normal  (AKR) 
mouse serum and  GPC.  After  treatment,  equivalent  numbers of viable  cells 
were added to the target cells to compare the degree of cytotoxicity between the 
two groups. It was found that spleen cells taken from mice before the 6th day 374  EFFECTOR  CELLS  AGAINST  AN  ALLOGENEIC  LYMPHOMA. 
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FIG. 3.  Cytotoxic effect of CBA spleen cells.  Percent release of 125I 4- SEM from YAC 
cells in the presence of immune CBA spleen cells taken at various time intervals after i.nocula- 
tion with YAC cells. Dashed line represents isotope release in the presence of nonimmune CBA 
cells. Effector to target cell ratio, 100:1. 
TABLE  I 
Cytotoxic Elect of Immune Spleen and Mesenteric Lymph Node Cells 
Effector cell  Cell source  1~I release 
% 
None  --  10.2 
Nonimmune  Spleen  15.3 
Nonimmune  Mesenteric lymph node  17.0 
Immune  Spleen  77.0 
Immune  Mesenteric lymph node  54.6 
Animals primed with 107 YAC cells 6 days before spleen  and lymph nodes were removed 
for testing. 
Effector to target cell ratio, 100:1. 
after printing  (early  immune  spleens  or  EIS)  were  not  sensitive  to  antitheta 
serum  treatment  because  there  was  no  reduction  in  the  cytotoxicity observed 
(Fig. 4).  However, after this time and  during  the peak  and  later stages of the 
response,  there  was  suppression  of cytotoxicity in  these  spleens  (late immune 
spleens or LIS) after antitheta serum treatment. 
Since the spontaneous  release of isotope from the target cells varied consider- 
ably at different times of assay, we also performed experiments where groups of JAMES FORM_AN AND  SVEN  BRITTON 
TABLE  II 
Specificity of Cytotoxic Effect 
375 
Days after host  Effector  to  Release  of 12~I  Release  of 125I 
Donor cells  Host  priming test  performed  target cell ratio  with  nonimmUnecells  withcellsimmune 
%  % 
A/Sn  CBA  7  100:1  10.7  40.3 
CBA  A  7  100:1  10.7  11.4 
YAC  CBA  4  60:1  10.7  48.7 
30:1  11.6  33.3 
YAC  A/Sn  4  60:1  9.4  8.8 
30:1  10.5  9.2 
YAC  CBA  3  100:1  19.9  46.0 
YBB  CBA  3  100:1  19.9  26.8 
Mice were primed with 10 7 live spleen or tumor cells. 
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Cytotoxic effect  of antitheta  serum-treated spleen cells.  Percent  release of  125I 
from YAC cells in the presence of immune CBA spleen cells  -- percent release of a25I in the 
presence of nonimmune CBA spleen cells.  Animals were primed with YAC cells and tested at 
various time intervals. --,  immune spleen cells pretreated with AKR serum and GPC;  or 
..... , antitheta serum "A" and GPC. Effector to target cell ratio, 100:1. 376  EFFECTOR  CELLS  AGAINST  AN  ALLOGENEIC  LYM~PEOMA 
mice were inoculated with tumor cells on different days and then tested all on 
the same day.  Similar results were observed in this case; i.e. killer cells from 
EIS were not theta sensitive nor was the presence of theta-positive cells neces- 
sary for  the expression of cytotoxicity, while the mediation of cytotoxicity in 
LIS required, at the least, the presence of a  theta-positive cell (Fig. 5). Cyto- 
toxicity in LIS was always inhibited by the  antitheta serum  treatments, but 
the amount of suppression varied and was never complete as others have re- 
ported  (6). This may have been due to either the persistence of some T  cells 
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Flo. 5.  Cytotoxic effect of antitheta serum-treated spleen cells. Percent release of 125I 4- 
SEM from YAC cells in the presence of immune CBA spleen cells. Mice were primed at differ- 
ent time intervals with YAC cells and their spleens were tested on the same day. ---,  CBA 
immune spleens pretreated with AKR serum and GPC; .....  , CBA immune spleens pretreated 
with antitheta serum "H" and GPC in panel a, and "E" in panel b;  .... , percent release 
of 12aI in the presence of nonimmune spleen cells. Effector to target cell ratio, 100:1. 
after the treatments (26), or residual activity of a postulated antitheta serum- 
resistant cell population existing in the EIS. 
The rate of radioiodide release from YAC cells incubated with day 5 immune 
spleens (Fig. 6)  was rapid, with the peak rate occurring during the first 6 h  of 
the test. In this experiment, as well as in some of the others we performed (e.g., 
Fig.  4),  an  enrichment or  increase  in  cytotoxicity was  seen  after  antitheta 
serum pretreatment of early immune cells. 
To test the efficiency of the antitheta sera used in the above experiments in 
removing those T  cells required for "helper" activity, we  tested  the ability of 
serum-treated  spleen  ceils  to  respond  to  heterologous  erythrocytes  in  vitro 
where the number of PFC was measured 4  days after the addition of SRBC. JAMES  FORMAN AND  SVEN BRITTON  377 
We found that  these  antitheta  sara were  able  to inhibit  such a  response  by 
60-95 % (Table III) similarly to what others have observed (27). 
Effect of Iron Treatments of Immune Spleen Cells.--Since the cell participating 
in EIS responding to YAC was not sensitive to antitheta serum, we wanted to 
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FIO. 6.  Rate of 125I release from YAC cells in the presence of immune CBA spleen cells. 
Index of 12~1 release from YAC cells in the presence of immune CBA spleen cells taken from 
mice primed 5 days previously with YAC ceils.  Spleen cells were pretreated with; --,  AKR 
serum and GPC; or ..... , antitheta serum "B"  and GPC. Isotope release was determined at 
6-h intervals after the start of the assay. Effector to target cell ratio, 100:1. 
TABLE  III 
The Effect of Treatment of (A  X  CBA)F1 Spleen Cells with Antitheta or Normal Mouse (NMS) 
Sara and GPC on Their Ability to Make PFC against SRBC. Test after 4 days Culture 
Dilution of  No. of viable  Total no. of PFC  --  Reduction in 
Exp.  Spleen cell pretreatment  antithera sara  cells recovered  background/  PFC after  antithera 
and GPC  (X  10  6)  culture  pretreatment 
% 
I  NMS  1/3  7.6  388 
Antitheta "D"  1/3  7.4  1ll  72 
2  NMS  1/1  5.8  545 
Antitheta "B"  1/1  6.4  217  60 
NMS  1/3  6.6  422 
Antitheta "A"  1/3  3,8  23  95 
Antitheta "H"  1/3  4.6  32  92 378  EFFECTOR  CELLS  AGAINST  AN  ALLOGENEIC  LYMPHOMA 
determine if nonlymphoid cells were involved in mediating cytotoxicity at this 
time. Animals primed 3  days before testing had  their spleens removed and a 
portion  of  the  cells  were  pretreated  with  carbonyl  iron  powder  in  order  to 
remove adherent cells (28).  The cells were then assayed for their cytotoxicity 
against  YAC  and  compared with  equivalent  numbers  of  nontreated  spleen 
cells.  In Fig. 7, it can be seen that such treatments did not reduce the amount 
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FIG.  7.  Cytotoxic effect of carbonyl iron-treated immune CBA spleen cells.  Percent release 
of ~2aI from YAC cells in the presence of CBA spleen cells taken from mice primed 3 days pre- 
viously with YAC cells.  Spleen cells were pretreated with carbonyl iron powder, - .... ; or un- 
treated, ---.  ........  , isotope release in the presence of nonimmune cells. 
of isotope release from target cells,  and  thus phagocytosing or adherent  cells 
do not appear to participate in this stage of the immune response. 
P~ffecl of Anlitargel  Cell Immune Sera  on Cytotoxicity  Caused  by Normal and 
Immune  Spleen Cells.--When normal  spleen cells,  purified by treatment with 
carbonyl iron, were added to YAC cells in the presence of sera from CBA mice 
in  the  process of  tumor  rejection  or  a  hyperimmune A.CA  anti-H-2  a serum, 
cytotoxicity  was  induced  at  serum  dilutions  as  low  as  10  a.  This  antibody- 
induced cytotoxicity has been described previously (see references 7 and 8 for JAMES  FORMAN  AND  SVEN  BRITTON  379 
review) and will be reported in this series later (manuscript in preparation). In 
these  experiments,  we  wanted  to  study whether  spleen  cell populations  that 
varied in their sensitivity to antitheta serum treatments also responded differ- 
ently in  the presence of antitarget  cell  antisera  with  regard  to  expression of 
cytotoxicity. 
CBA mice were immunized with YAC  cells at different time intervals and 
sacrificed on  the  same day.  Their spleen  cells were pretreated  with  carbonyl 
iron to remove adherent cells and then added to dishes containing target cells. 
At the same time an A.CA anti-A or normal A.CA heat-inactivated serum was 
added to the cultures at varying dilutions. In Fig. 8, results of such experiments 
are presented. The tumor cells released 20 % of their label when incubated with 
normal CBA spleen cells.  When the target cells were mixed with day 3 or day 
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Fro. 8.  Effect of anti-target cell  immune serum on thc cytotoxic  effect  of immune CBA 
spleen cells.  Percent release of 125I from YAC cells in the presence of CBA spleen cells taken 
from mice primed 3  (O) or 9  (Q) days previously with YAC cells.  A, nonimmune mice; ..... , 
A. CA anti-A/Sn serum; or  , normal A. CA serum added to the cultures at various dilu- 
tions. Immune serum was obtained from A. CA mice after receiving four weekly injections of 
A/Sn spleen cells. Effector to target cell ratio, 100:1. 380  EFFECTOR  CELLS  AGAINST  AN  ALLOGENEIC  LYMPHOMA 
9 immune cells, approximately 40 and 95 % of the isotope was released, respec- 
tively, in the presence of normal mouse serum. When immune mouse serum was 
added  to  dishes  containing  day 3  immune  cells,  cytotoxicity was greatly in- 
creased  compared  with  those  groups  with  normal  mouse  serum.  However, 
when the same antiserum at the same dilutions was added to dishes with day 9 
immune cells (Fig. 8) or day 10 or day 21  immune cells (data not shown)  the 
release of isotope was reduced. Thus, in the presence of immune serum,  there 
was a  differential cytotoxic effect of spleen cell populations, depending on the 
time after priming that they were tested. 
Characteristics  of  the  Killing  Eaficiency of  Immune  Spleen  Cells.--When 
varying numbers of effector cells were added  to a  standard  number of target 
cells,  the degree of isotope release increased linearly with the log of the effector 
to target cell  ratio. A plot of the data obtained from testing spleens taken at 
two different time intervals after priming showed that there were more effector 
cells on day 7 of the immune response compared with day 3 (Fig. 9). However, 
as the effector to target cell ratio was increased, target cell lysis in the presence 
of the day 7 immune cells increased at a  greater rate than in  the presence of 
cells taken 3 days after priming, suggesting a different efficiency or character of 
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FIO. 9.  Cytotoxic effect of day 3 and day 7 immune CBA spleen cells. Percent release of 
125I from YAC cells in the presence of CBA spleen cells taken from mice primed 7 days (0)  or 
3 days (A) previously with YAC cells. -----, release of isotope in the presence of nonimmune 
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cell  killing (15). This finding is consistent with either a  different effector cell 
operating at  these  time intervals,  or the  same cell but at different stages  of 
maturation. 
DISCUSSION 
Before discussing the results of the host response we would like to comment 
on the assay system used here. This is important because the amount of cyto- 
toxicity observed during the early phase of the immune response in the pres- 
ence of spleen cells was small and required a sensitive method for its demonstra- 
tion. In our hands,  51Cr labeling involved considerable handling of our target 
cells which resulted in  a  high  spontaneous isotope release at  the  end of the 
assay (after 16 h). Therefore, we selected [12~I]UdR as the indicator of cell death 
since it offered advantages such as (a) ease of labeling cells under usual tissue 
culture conditions, (b) minimal handling after labeling, and (c) absence of leak- 
age from viable cells. However, since spontaneous isotope release is a function 
of the target cell's ability to survive the conditions of the assay system used, 
the  suitability  of a  particular  labeling  method  will  vary with  different test 
systems. 
Others have shown that 125I release from [~2~I]UdR-labeled cells is an accurate 
indicator of cell death (24). In these experiments, we found that this label was 
released from target cells in proportion to the number of immune cells present 
and similar to 51Cr release when the cells were doubly labeled. After 16 h incu- 
bation of target cells with immune spleen cells  taken from mice primed 3-4 
days before testing, 40-50% of the total label was found in the supernatant and 
by day 7  this  figure rose  to greater than  90%,  while background release of 
~25I in the presence of nonimmune spleen cells was usually about 20 %. Further, 
the  uptake  of  [12~I]UdR by  the  cultured  tumor  cell  suspensions  during  the 
labeling procedure was rapid which allowed the usage of the target cells on the 
labeling day. 
Non-thymus-derived  lymphoid  cells  have  been  demonstrated  to  act  as 
killer cells in cell-mediated cytotoxic reactions when the target cell  has been 
sensitized with antitarget antibody (8, 9, 29). The fact that the target cell can 
be lysed in the presence of purified spleen preparations when thymus-derived 
and phagocytozing cells have been removed indicates that bursal equivalent of 
B cells are capable of mediating this effect3 
Reports of experiments done in vivo have indicated that serum antibody may 
indeed play a  role in  graft  rejection  (11-13).  Whether this  is due  to  a  cell- 
mediated mechanism, however, is still not clear. 
In  this  report we have presented evidence that  is  compatible with  a  cell- 
mediated  cytotoxic response  that  may involve non-thymus-derived lympho- 
cytes as  the  final  effector cells in graft destruction. Out data show  that  the 
cytotoxic effect of spleen cells taken soon after host priming was not sensitive to 
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peak and later stages of the response were pretreated with antitheta sera, sup- 
pression of cytotoxicity occurred. This indicates that  a  cell  lacking or low in 
theta antigenic content is the early killer cell, with a second theta-positive cell 
participating  at  a  later stage of the imnmne response and  required  to attain 
peak cytotoxicity. The second (theta-positive) cell may be a component of the 
recirculating lymphocyte pool migrating from an extra splenic site to the spleen 
(30)  or be generated from the thynms-derived antigen recognizing cell popula- 
tion residing in the spleen before sensitization  (31). Whether this second cell is 
the  actual  killer  cell,  though,  cannot be determined  from these  experiments. 
Since  spleen  cell  cytotoxicity  was  decreased  but  not  completely eliminated 
during the peak response by the antitheta sera treatments, this residual killing 
may indicate that these postulated non-theta-positive cells persist throughout 
the  immune  response,  although  we do  not  exclude  the  possibility that  these 
treatments  leave  some  surviving T  cells  as  others  have  found  (23,  26,  27). 
If  the  antitheta-resistant  cell  is  a  B  cell  participating  in  antibody-induced 
cytotoxicity,  then  the  relatively weak  cytotoxic effect exerted  by these  cells 
may indicate that some YAC cells are resistant to cytolysis by this mechanism. 
The  fact  that  the  antitheta  sera  suppressed  the  primary in vitro PFC  re- 
sponse to SRBC as well as the cytotoxic effect of spleen cells taken from mice 
during  the peak and later stages of the  immune response indicates  that such 
treatments were effective in inhibiting T  cell  function.  Further,  although the 
early proliferating T  cell responding to allogeneic tissue in our system may be a 
large pyrininophilic blast cell as others have found (1, 14), it is unlikely that this 
cell  is resistant  to  antitheta  sera  since  it  has been  demonstrated  that  PHA- 
stimulated  blast  cells  are  susceptible  to  such  treatment  (32).  However,  the 
theta-resistant effector cell seen in the EIS could still be a T  cell at some stage 
of maturation or differentiation  that is resistant  to the antisera treatment or 
one that does not participate in helper cell activity. 
When spleen ceils from day 3 imnmne mice were treated with carbonyl iron 
powder to remove adherent  cells (28),  there was no decrease in  the cytotoxic 
effect to  YAC.  Thus,  while  macrophages have been  shown  to participate  in 
cell-mediated immune responses (33,  34),  it is unlikely that this cell  type was 
the  theta-resistant killer cell  in  these  experiments. 
This host response was also demonstrated to be specific for the H-2  antigens 
of the H-3 ~  allele since  H-E a  anti-H-2  k spleen cells did not kill  YAC.  Tumor- 
specific immunity  due  to  tumor-specific antigens  induced  by Moloney virus 
was  probably  minimal  with  this  immunizing  regimen  since  CBA  anti-YBB 
(a CBA Moloney virus-induced leukemia) cells exerted only slight cytotoxicity 
against YAC cells. 
A second difference between these early and later immune spleen cell popu- 
lations was observed in the presence of immune serum. Such serum was capable 
of  inducing  cytotoxicity  against  YAC  cells  using  nonimmune,  iron-purified, 
spleen cell  populations  as effector cells.  However, in  the presence of immune JAMES  FORMAN  AND  SVEN  BRITTON  383 
spleen cell populations, the same serum caused an enhanced cytotoxicity when 
cells were  taken from EIS and  inhibited  cells derived from LIS. During  the 
early phase  of  the  immune response it  is probable  that  this  serum  induced 
unsensitized  spleen  cells  into  cytotoxicity and  thus  augmented  the  already 
present cytotoxic effect. The inhibition  of the peak phase of cytotoxicity by 
the  same serum  could  have been a  result  of direct  action  on T  cells and/or 
inhibition of B cell killing by high antiserum titers. 
It has been  demonstrated  that  sera from tumor-bearing animals  taken  at 
various  stages  of  tumor  development  and  regression  possess  characteristics 
that enable them to inhibit or promote immune cell  function  (35).  According 
to the results obtained in this investigation, these "blocking" and "unblocking" 
sera may vary in their function depending on the stage of the immune response 
the effector cells are tested at. 
A  third  difference  in  these  two  types  of immune  spleen  populations  was 
noted with regard to the slopes of the killing curves when the effector to target 
cell ratio was varied. Thus,  target cell  lysis in  the presence of day 7 immune 
cells increased at a greater rate than in the presence of cells tested 3 days after 
priming. Such findings have been reported previously by Canty et al. (15)  who 
suggested that this reflects a difference in the activity of the ilnmune cell. We 
also feel that this can indicate either two different cell types as killer cells in the 
immune response or the same cell at a different stage of maturation. This may 
also  represent  an  increase  in  receptor  affinity on  the  killer  cell  which  could 
occur during the development of the host immune response. 
It is not known what type of grafted cell can induce a  response in the host 
that would favor antibody-induced killing. The susceptibility of the target cell 
to lysis in this kind of cytotoxicity may be related to the expression and dis- 
tribution of the relevant antigens on the cell membrane, which has been shown 
to  be  an  important  factor with  respect  to  complement-dependent  lysis  and 
enhancement of tumor growth  (36-38).  Finally, one should not expect to find 
this  B  cell  effector  mechanism  operational  during  the  course  of  the  host's 
response unless  it can be shown  that  the  tumor cell  is sensitive to antibody- 
induced  killing using normal lymphoid cells and immune sera obtained from 
the appropriate host during the time of tumor rejection. 
SUMMARY 
The cytotoxic effect of spleen cells from H-2 allogeneic mice was tested  in 
vitro against an A  strain leukemia (YAC) labeled with [125I]iododeoxyuridine. 
After the mice were primed with tumor cells,  significant and specific H-2 im- 
munity was detected on day 3 and peak cytotoxicity was observed between 7 
and 14 days after priming. Two effector cells appear to be involved in the host 
response, because spleens taken from mice soon after priming were not sensi- 
tive  to  antitheta  sera  and  complement  while  those  taken  during  the  peak 
stages of the response showed a  marked reduction  in cytotoxicity after treat- 384  EFFECTOR  CELLS  AGAINST  AN  ALLOGENEIC  LYMPHO1VIA 
ment.  Macrophages  were  not  involved,  since  removal  of  these  cells  by  the 
carbonyl iron method did not result in any reduction in cytotoxicity. Immune 
serum that was capable of inducing cell-mediated cytotoxicity in normal spleen 
cell populations  also  augmented  cytotoxicity of spleen  cells  taken  from mice 
primed  3  days previously.  However,  when  spleen  ceils  were  taken  from mice 
during  the  peak phase  of the  immune  response,  the  same  serum  at  the  same 
dilutions  inhibited  the  preexisting  cytotoxicity.  A  difference  was  also  de- 
tected in the killing efficiencies between early and late immune cells. 
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